Australia's Zelira Therapeutics jumps on partial receipt of license fee

Zelira Therapeutics

10/01/2022 02:47

** Shares of Zelira Therapeutics Ltd  ZLD.AX  rise as much
as 9.7% to A$0.034, hitting their highest level since Dec 20
    **  The biopharmaceutical co says it got $250,000 of its
licensing fee of $1 mln from DRCN Holdings for its enhanced
distillate capture and dissolution matrix technology 
 urn:newsml:reuters.com:*:nASX20D2sB
    ** Co expects to receive the remaining $750,000 in Q1 CY2022
    ** Stock posts its biggest intraday pct gain since Dec 22 
    ** Zelira stock down 64.1% in 2021
        

 (Reporting by Navya Mittal)
 ((Navya.Mittal@thomsonreuters.com;))